ArticleScience advances2022
A programmable high-expression yeast platform responsive to user-defined signals.
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Systematic optimization ofEngineering microbiology · 2026Review
- Yeast species resource exploration and application in cell factories.Synthetic and systems biotechnology · 2026Review
- Engineering heterologous core promoters to optimize the SES expression system forSynthetic and systems biotechnology · 2026Article
- Development and Application of a Cumate-Inducible Promoter, PMicrobial biotechnology · 2026Article
- Synthetic tunable promoters for flexible control of multi-gene expression in mammalian cells.Journal of advanced research · 2025Article
- Design and construction of light-regulated gene transcription and protein translation systems in yeast P. Pastoris.Journal of advanced research · 2025Article
- Rational design and characterization of enhanced alcohol-inducible synthetic promoters inApplied and environmental microbiology · 2025Article
- Advancing recombinant protein expression in Komagataella phaffii: opportunities and challenges.FEMS yeast research · 2025Review
- Transcriptome analysis reveals methanol metabolism variations for the growth damage caused by overexpression of chimeric transactivators inSynthetic and systems biotechnology · 2025Article
- De novo biosynthesis and nicotinamide biotransformation of nicotinamide mononucleotide by engineered yeast cells.Microbial biotechnology · 2024Article
- OptoLacI: optogenetically engineered lactose operon repressor LacI responsive to light instead of IPTG.Nucleic acids research · 2024Article
- Applications of the Methylotrophic YeastJournal of fungi (Basel, Switzerland) · 2024Review
- Promoter engineering enables precise metabolic regulation towards efficient β-elemene production inSynthetic and systems biotechnology · 2024Article
- Edible mycelium bioengineered for enhanced nutritional value and sensory appeal using a modular synthetic biology toolkit.Nature communications · 2024Article
- Identification of a novel growth-associated promoter for biphasic expression of heterogenous proteins inApplied and environmental microbiology · 2024Article
- Genetic tools for metabolic engineering ofEngineering microbiology · 2023Review
- Biosynthesis of High-Active Hemoproteins by the Efficient Heme-Supply Pichia Pastoris Chassis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- An inducible Komagataella phaffii system for protein expression using sorbitol dehydrogenase promoter.Biotechnology letters · 2023Article
- Recent Advances in CRISPR-Cas Technologies for Synthetic Biology.Journal of microbiology (Seoul, Korea) · 2023Review
- Use of CRISPR-Cas tools to engineer Trichoderma species.Microbial biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapidly growing yeasts with appropriate posttranslational modifications are favored hosts for protein production in the biopharmaceutical industry. However, limited production capacity and intricate transcription regulation restrict their application and adaptability. Here, we describe a programmable high-expression yeast platform, SynPic-X, which responds to defined signals and is broadly applicable. We demonstrated that a synthetic improved transcriptional signal amplification device (iTSAD) with a bacterial-yeast transactivator and bacterial-yeast promoter markedly increased expression capacity in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.